Internal Medicine, Rheumatology · Anniston, AL
NPI
1083635015
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1010 Christine Ave
Anniston, AL, 36207
Phone (256) 236-5631
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
173,980 services
Medicare patients, 2024
833
Average age 73
Drug cost, 2024
$4.3M
10,826 prescriptions
Company payments, 2025
$3,943
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vishala Chindalore was code J1602 (injection, golimumab, 1 mg, for intravenous use), 45,294 times for 50 patients. In total Vishala Chindalore billed 173,980 services in 67 codes, and Medicare paid $2.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-04-16.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 45,294 | 50 | $8.69 | $394K |
| J0897 Injection, denosumab, 1 mg | Office | 14,940 | 138 | $20.06 | $300K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 14,490 | 12 | $8.61 | $125K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,925 | 13 | $33.84 | $302K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 6,480 | 20 | $24.81 | $161K |
| 99214 Office E&M - Established | Office | 2,085 | 675 | $81.61 | $170K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,240 | 13 | $0.10 | $129 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 665 | 100 | $0.51 | $338 |
| 96372 Injection Administration | Office | 605 | 181 | $10.09 | $6,106 |
| 36415 Venipuncture Blood Collection | Office | 525 | 102 | $8.42 | $4,419 |
| 96413 Chemotherapy Administration | Office | 502 | 79 | $85.98 | $43K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 220 | 44 | $4.78 | $1,052 |
| 96365 Intravenous Infusion, Hydration | Office | 203 | 67 | $42.49 | $8,626 |
| 99213 Office E&M - Established | Office | 186 | 141 | $55.64 | $10K |
| 73120 X-ray - Upper Extremity | Office | 118 | 94 | $21.14 | $2,494 |
By year: 2022 $2.4M for 157,690 services; 2023 $2.5M for 173,450 services; 2024 $2.3M for 173,980 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 525 | 102 | $8.42 | $4,419 |
| 83036 Blood Count | 30 | 30 | $9.52 | $286 |
Medicare prescription drug claims, 2024
In 2024, the drug Vishala Chindalore prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 1,431 prescriptions and refills. In total Vishala Chindalore wrote 10,826 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 1,431 | 2,058 | 270 | $35K |
| Hydroxychloroquine Sulfate Generic | 1,248 | 1,705 | 235 | $43K |
| Prednisone Generic | 1,195 | 1,459 | 301 | $4,771 |
| Sulfasalazine Generic | 921 | 1,306 | 210 | $16K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 844 | 845 | 95 | $16K |
| Gabapentin Generic | 542 | 688 | 99 | $5,753 |
| Tramadol Hcl Generic | 434 | 450 | 90 | $2,836 |
| Pregabalin Generic | 294 | 354 | 38 | $6,526 |
| Leflunomide Generic | 270 | 434 | 61 | $16K |
| Allopurinol Generic | 265 | 419 | 54 | $2,514 |
| Cyclobenzaprine Hcl Generic | 265 | 329 | 58 | $1,268 |
| Meloxicam Generic | 244 | 332 | 63 | $735 |
| Colchicine Generic | 229 | 321 | 65 | $16K |
| Tizanidine Hcl Generic | 202 | 254 | 35 | $1,798 |
| Celecoxib Generic | 197 | 299 | 37 | $7,222 |
Brand drugs: - claims; generic drugs: 9,290 claims; opioid claims: 1,570.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vishala Chindalore $3,943 ($3,177 in general payments such as food, travel and fees and $767 for research) from 20 companies. The largest payer was F. Hoffmann-La Roche AG with $767.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 1 | $767 |
| Abbvie Inc. ABBV | 27 | $582 |
| Amgen Inc. AMGN | 30 | $464 |
| UCB, Inc. UCB.BR | 19 | $335 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $330 |
| Pfizer Inc. PFE | 20 | $282 |
| Janssen Biotech, Inc. JNJ | 10 | $268 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $243 |
| GlaxoSmithKline, LLC. GSK | 15 | $238 |
| Atland Pharmaceuticals, LLC | 1 | $125 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.